


Study with the several resources on Docsity
Earn points by helping other students or get them with a premium plan
Prepare for your exams
Study with the several resources on Docsity
Earn points to download
Earn points by helping other students or get them with a premium plan
Community
Ask the community for help and clear up your study doubts
Discover the best universities in your country according to Docsity users
Free resources
Download our free guides on studying techniques, anxiety management strategies, and thesis advice from Docsity tutors
TROPONIN I-CHECK-1 is a rapid quantitative assay for the detection of cardiac Troponin I in serum, plasma or whole blood samples. The method employs a unique ...
Typology: Study notes
1 / 4
This page cannot be seen from the preview
Don't miss anything!
Troponin I (TnI) is one of the thin filament-associated regulatory proteins of muscle (1). It is encoded by three different genes that are differentially expressed by the various muscle tissues, resulting in slow – and fast skeletal and cardiac TnI isoforms (2). The unique amino acid sequence of cTnI makes it an ideal candidate for the laboratory detection of acute myocardial infarction (AMI) and has facilitated the development of monoclonal antibodies that do not cross-react with skeletal muscle troponins (3). Published studies from various groups have demonstrated the utility of cTnI measurement for detection of AMI (3, 4, 6, 7). CK-MB and cTnI both elevated beyond normal reference limits within 4-6 hours after infarction. Typical reference limits were, as reported by Bodor et al (3), 6.7 ng/mL for CK-MB and 3.1 ng/mL for cTnI. Likewise, each report sites similar time frames for the peak values of CK-MB and cTnI : CK-MB peaked in 13-15 hours, cTnI in 11- hours. Typical ranges were 39 –185 ng/mL for CK-MB and 18.5 – 188 ng/mL for cTnI (5). However, CK-MB level returns to normal after 36-48 hours, while levels of cTnI remains elevated for up to 6-10 days. The level of cTnI is very low in normal healthy people, and not detected in patients with skeletal muscle injury. Therefore, cTnI is a specific marker for diagnosis of AMI.
TROPONIN I-CHECK-1 is a rapid quantitative assay for the detection of cardiac Troponin I in serum, plasma or whole blood samples. The method employs a unique combination of monoclonal dye conjugate and polyclonal solid phase antibodies to identify troponin in the test samples with a high degree of sensitivity.
As the test sample flows through the absorbent device, the antibody- dye conjugate binds to the troponin forming an antibody-antigen complex. This complex binds to the anti troponin antibody in the reaction zone (T) and produces a pink-rose colour band.
In the absence of troponin, there is no band in the reaction zone (T). The reaction mixture continues flowing through the absorbent device past the reactive zone (T) and control zone (C). Unbound conjugate binds to the reagents in the control zone (C), producing a pink-rose colour band, demonstrating that the reagents are functioning correctly.
Each kit contains everything needed to perform 10 or 20 tests. 1- TROPONIN I -CHECK-1 reaction devices: 10 20 2- Disposable plastic pipettes: 10 20 3- Diluent in a dropper bottle: 2.5mL 5mL 4- Instruction leaflet: 1 1 5- Controls (Optional): Positive control (ref. V280) and Negative control (ref. V281) : a freeze-dried preparation of a non-infectious compound in diluted human serum, tested and found negative for anti-HIV, anti-HCV and HBs antigen, containing 0.05 % sodium azide is optionally available as a positive and negative control (1x 0.25 mL). The concentration range is indicated on the vial label.
1- This test is designed for in vitro diagnostic use and professional use only. 2- Read carefully the instructions before using this test. 3- Handle all specimens as if they contained infectious agents. When the assay procedure is completed, dispose of specimens carefully after autoclaving them for at least one hour. Alternatively, they can be treated with 0.5% to 1% solution of sodium hypochlorite for one hour before disposal. 4- Wear protective clothing such as laboratory coats and disposable gloves while assaying samples. 5- Do not eat, drink or smoke in the area where specimens and kit reagents are handled. 6- Avoid any contact between hands and eyes or nose during specimen collection and testing. 7- Do not use beyond the expiry date which appears on the package label. 8- Do not use a test from a damaged protective wrapper.
1- TROPONIN I rapid test is performed on human serum, plasma or whole blood. 2- The specimen should be collected under the standard laboratory conditions (aseptically in such a way as to avoid haemolysis). 3- If anticoagulant is needed, only citrate, EDTA or heparin should be used. 4- Each specimen should be treated as if potentially infectious. 5- Whole blood samples should be tested immediately (< 4 hours). Finger prick samples should be assayed just after collection. 6- If the test is to be run within 48 hours after collection the specimen should be stored in the refrigerator (+2°C to +8°C). If testing is delayed more than 48 hours, the specimen should be frozen. The frozen specimen must be completely thawed, thoroughly mixed and brought to room temperature prior to testing. Avoid repeated freezing and thawing. 7- In case of cloudiness, high viscosity or presence of particulate matter into the serum specimen, it should be diluted with equal volume (V/V) of diluting buffer (not provided but available upon request) before testing.
a) Control testing
1– Allow samples and TROPONIN I -CHECK-1 test devices to come to room temperature prior to testing. 2– Remove the reaction device from its protective wrapper by tearing along the split. 3– Label device with the patient’s name or control number. 4– Fill the plastic pipette with sample or control and, by holding it vertically, dispense one drop (25 μL) of serum or plasma into sample well (Z). If the whole blood is used, dispense two drops (50 μL) into the sample well (Z) and wait for the blood sample to be fully absorbed before adding diluent. 5– Hold the dropper bottle vertically and slowly add exactly 4 drops of diluent (150 μL) into the sample well (Z) with an interval of 2-3 seconds between each drop. 6– Read the result (in ng/mL ) after 20 minutes, either using the immediate or countdown reading mode (see corresponding leaflet).
For general instructions describing how to use the VEDALAB’s rapid tests readers, refer to the corresponding leaflet.
The linearity measuring range is 0-50 ng/mL.
1- Standards A study has been performed using five concentrations of DADE-BEHRING calibrators determined in duplicate on TROPONIN I-CHECK-1 rapid tests. The results show the good correlation of the values obtained with TROPONIN I-CHECK-1 on VEDALAB’s reader.
Correlation figures : y = 1.258 x – 0. r = 0.
2. Add 4 drops
1. Add 1 drop
No hook effect has been observed up to 5 μg/mL both for complexed and purified form of Troponin I.
Within run precision was evaluated by using 26 replicates of three commercially available references containing 4.29, 17.33 and 36.87 ng/mL of TROPONIN I as determined with quantitative TROPONIN I-CHECK-1 for VEDALAB’s reader. The obtained CVs (coefficient of variation) were respectively equal to 9.91%, 7.55% and 9.45%.
No interference was observed with the following substances:
No interference was observed on negative serum containing CRP concentrations up to 96 mg/mL and RF concentrations up to 3,072 IU/mL. Whole blood and plasma samples with different anticoagulants were assayed indicating no matrix effect for citrate, EDTA and heparin.
1- As for any diagnostic procedure, the physician should confirm the data obtained using this test by other clinical methods. 2- Any Troponin I concentration close or higher than 0.8 ng/mL for serum and plasma samples or 1.0 ng/mL for blood samples may suggest a possible AMI. The time required for blood cTnI level to reach the upper limit of normal has been found to be 4-6 hours after the onset, and then remains elevated for 6-10 days in some cases. Therefore, a negative result within the first hours of the onset of symptoms does not rule out AMI with certainty. If suspected, repeat the test at appropriate intervals. 3- Use only fresh whole blood samples (< 4 hours) when test is performed with blood samples. Finger prick samples should be assayed just after collection. 4- In case of high RF (rheumatoid factor) or CRP (C-reactive protein) concentrations (high levels indicate acute infections), the test could exceptionally show a positive result. 5- In case of delayed reading time, i.e. over 20-25 minutes, the test could also show sometimes positive results. 6- The test is designed to eliminate the potential interference of human antibodies to murine IgG (HAMA). However, high level of HAMA could give falsely positive results. 7- This format of test is to be only used with VEDALAB’s rapid test readers. 8- If the reading time (20 minutes) is not strictly respected, wrong results will be obtained. 9- This format of test should not be used for visual reading. 10- As for any diagnostic method or for any measurements through analysers, there is a variability of the obtained result. Therefore, a confidence range of +/-25% should be considered for the final value and for the clinical significance of the result.
1- Perry S.V. The regulation of contractile activity in muscle. Biochem Soc Trans 1979; 7; 593-617. 2- Bucher E.A., Maisonpierre P.C., Konieczny S.F., Emerson C.P. Jr. Expression of the Troponin complex genes : transcriptional coactivation during myoblast differentiation and independent control in heart and skeletal muscles. Mol Cell Biol 1988;8 : 4134-42. 3- Bodor G.S., Porter S., Landt Y., Ladenson J.H. Development of monoclonal antibodies for an assay of cardiac Troponin-I and preliminary results in suspected cases of myocardial infarction. Clin Chem 1992; 38: 2203-14. 4- Cummins B., Auckland M.L., Cummins P. Cardiac-specific Troponin-I radioimmunoassay in the diagnosis of acute myocardial infarction. Am Heart J 1987; 113: 1333-44. 5- Bodor G., Porter S., Ladenson J. Human cardiac Troponin I measurement in suspected myocardial infarction with a double monoclonal antibody sandwich ELISA. Clin. Chem. 1990, 36 (6):
The joint European Society of Cardiology/American College of cardiology committee. Myocardial Infarction redefined. Journal of American College of cardiology. 36 (3) : 959-969. 2000. 7- Apple F.S., Wu A. Myocardial infarction redefined : role of cardiac troponin testing. Clinical Chemistry. Vol. 47 no.3. 2001.
Manufactured by VEDALAB - France